Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphoma
These findings corroborate that employing T cells collected prior to frontline chemotherapy could enhance the effectiveness of CAR T-cell therapy and improve patient outcomes.
Authors
- Mareike Frick
- David R. Busch (ORCID: https://orcid.org/0000-0002-9488-944X)
- Annette Künkele (ORCID: https://orcid.org/0000-0002-8406-5412)
- Il‐Kang Na (ORCID: https://orcid.org/0000-0001-9902-5424)
- Andrea Stroux
- Julia K. Polansky (ORCID: https://orcid.org/0000-0003-4727-2540)
- Marco Frentsch (ORCID: https://orcid.org/0000-0003-3200-210X)
- Lars Bullinger (ORCID: https://orcid.org/0000-0002-5890-5510)
- Benedikt Obermayer (ORCID: https://orcid.org/0000-0002-9116-630X)
- Frédérik Damm (ORCID: https://orcid.org/0000-0001-5553-1173)
- Charlotte Junkuhn
- Phillip Schiele (ORCID: https://orcid.org/0000-0002-2342-3597)
- Olaf Penack (ORCID: https://orcid.org/0000-0003-4876-802X)
- Frederik Hamm (ORCID: https://orcid.org/0009-0002-2482-9916)
- Annette O. Walter
Institutions
- Baylor College of Medicine (US)
- Humboldt-Universität zu Berlin (DE)
- German Rheumatism Research Centre (DE)
- German Cancer Society (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/jitc-2024-010709
- Citations
- 14
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 14.64
Funders
- Novartis Pharma